Русский / English
Enter the query
Petrovax Pharm
the company makes significant investments in a broad range of research and development efforts

NPO Petrovax Pharm is a leading research and manufacturing company in Russia, producing pharmaceuticals and vaccines. Interros acquired a controlling stake in the company in 2013.

The company was founded in 1996 by a team of Russian researchers to develop, produce and commercialize original innovative pharmaceuticals.

The company’s main areas of focus are manufacturing flu vaccine to meet the national immunization calendar, and developing and producing immunobiologicals and long-acting nanobio drugs.

The company’s product line consists exclusively of innovative drugs and vaccines that NPO Petrovax Pharm successfully markets in Russia and the countries of the CIS and the EU.

CEO: Arkady Nekrasov

2 Dnepropetrovskaya st., Commercial Center Global City
Moscow, 117587, Russia

Tel: +7 (495) 984 2753
Fax: +7 (495) 984 2754 

History
2013
13.3 mln doses
of flu vaccine supplied to Russia’s regions
In accordance with the National Immunization Calendar, NPO Petrovax Pharm supplies 13.3 mln doses of Grippol® Plus vaccine. The primary vaccine recipients are the regions in the Far East Federal District that had experienced flooding: Khabarovsk Kray and the Amur and Jewish autonomous regions.

Working with Pfizer, NPO Petrovax Pharm implements a fully integrated production cycle to manufacture, monitor, and ensure quality control of the 13-valent pneumococcal conjugate vaccine, and produces the first few commercial batches. 

Over the course of the year, the company organizes a number of philanthropic initiatives. Together with Pfizer, it supports the Rostropovich-Vishnevskaya Foundation’s For the Health & Future of Children Program. Petrovax Pharm sends assistance to the flooded regions in the Far East Federal District and organizes a blood drive in conjunction with the Hematology Research Center’s Free Blood Donation Program.

The company begins work on a new development strategy. At the end of the year, Interros Holding enters into an agreement with NPO Petrovax Pharm to acquire a controlling stake in the company.
More
History
2014
16.9 mln doses
will be shipped to regionals with framework of the National Immunisation Schedule
The company of Vladimir Potanin, founder of the Interros Group, finalizes the acquisition of the controlling stake in NPO Petrovax Pharm, a Russian pharmaceutical company.
More
History
2015
>20 mln doses
vaccines against flue and pneumococcus Petrovax will produce in 2015
Will be shipped to regionals with framework of National Immunisation Schedule.
More
History
2016
Localized production of the Grippol® Plus flu vaccine in Belarus

February: Petrovax Pharm signs a trilateral strategic cooperation agreement in order to localize production of the Russian flu vaccine Grippol® Plus in Iran.

Petrovax Pharm launches Imoferaza®, an innovative ointment to treat problem areas and scar tissue after injuries, burns, acne, surgeries, and cosmetic procedures.

June: Petrovax Pharm and the German firm Boehringer Ingelheim sign an agreement to localize in Russia the full production cycle of state-of-the-art medicines for cardiovascular diseases.

July: Petrovax Pharm receives a Russian GMP compliance certificate following a directive of the Russian Federation Ministry of Industry and Trade.

August: Petrovax Pharm exports 1.5 million doses of Grippol® Plus flu vaccine to Kazakhstan.

October: Petrovax Pharm supplies more than 8.5 million doses of pediatric Grippol® Plus flu vaccine to meet the National Vaccination Schedule of the Russian Federation.

Polyoxidoniy, manufactured by Petrovax Pharm, receives a 2016 Russian Pharma Award for best pediatric immunity booster for acute upper respiratory infections.

Petrovax Pharm supplies 1.5 million doses of Grippol® Plus to Kazakhstan under the national drug and medical supplies procurement program.

More
History
2017
11 countries
import products manufactured by the company
Overview
NPO Petrovax Pharm is a leading research and manufacturing company in Russia, producing pharmaceuticals and vaccines. NPO Petrovax Pharm brings its research developments to full-scale manufacturing in its state-of-the-art high-tech biopharmaceutical plants. The company’s manufacturing is in full compliance with the GMP EU and ISO:9001 international standards. The company’s product line consists exclusively of innovative drugs and vaccines that NPO Petrovax Pharm successfully markets in Russia and the countries of the CIS and the EU.
More
Press Center
By the end of 2019, the companies intend to complete the transfer of technologies and to launch full-cycle production of innovative thrombolytic medicines at Petrovax Pharm’s production facility in the Moscow Region.
More
News
Vladimir Potanin, the owner and founder of Interros Group, one of the largest private investment companies in Russia, has completed acquisition of a controlling stake in Petrovax Pharm. For more details please visit www.petrovax.com
More
Events
At a conference on communication in the pharmaceutical industry, delegates discussed issues relevant to the pharmaceutical industry and emphasized the importance of open conversation and ongoing dialogue between the media and market experts.
More
NPO Petrovax Pharm passed an audit by the State Institute of Pharmaceuticals Quality Control of Slovakia, and was once again awarded the EU GMP production and quality management compliance certificate.
More
News
Interros Group is acquiring a controlling stake in NPO Petrovax Pharm, a Russian pharmaceutical company.  The parties signed the documents in Moscow today. Arkady Nekrasov and Natalia Puchkova, NPO Petrovax Pharm founders, will retain a stake in the company, and will continue to participate in business management. Financial terms of the deal are not disclosed.
More